Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof

Wyeth, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 61/124,796, filed Oct 17, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,729,672	Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 Wyeth LLC In force Term ends Feb 14, 2027 · Medium confidence	Wyeth LLC	In force	Term ends Feb 14, 2027	Term ends Feb 14, 2027	Medium confidence
US 8,173,814	Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof Wyeth LLC In force Term ends Oct 15, 2028 · High confidence	Wyeth LLC	In force	Term ends Oct 15, 2028	Term ends Oct 15, 2028	High confidence
US 9,139,558	Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4- (DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof Wyeth LLC In force Term ends Oct 15, 2028 · Medium confidence	Wyeth LLC	In force	Term ends Oct 15, 2028	Term ends Oct 15, 2028	Medium confidence
US 9,630,946	Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof Wyeth LLC In force Term ends Oct 15, 2028 · Medium confidence	Wyeth LLC	In force	Term ends Oct 15, 2028	Term ends Oct 15, 2028	Medium confidence
US 10,035,788	Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof Wyeth LLC In force Term ends Oct 15, 2028 · Medium confidence	Wyeth LLC	In force	Term ends Oct 15, 2028	Term ends Oct 15, 2028	Medium confidence
US 9,265,784	Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine Wyeth LLC In force Ends no later than Aug 4, 2029 · Medium confidence	Wyeth LLC	In force	Ends no later than Aug 4, 2029	Ends no later than Aug 4, 2029	Medium confidence
US 8,022,216	Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof Wyeth LLC In force Term ends Feb 19, 2030 · High confidence	Wyeth LLC	In force	Term ends Feb 19, 2030	Term ends Feb 19, 2030	High confidence
US 8,790,708	Coated Tablet Formulations and Uses Thereof Wyeth LLC In force Ends no later than Nov 5, 2030 · Medium confidence	Wyeth LLC	In force	Ends no later than Nov 5, 2030	Ends no later than Nov 5, 2030	Medium confidence
US 9,211,264	Coated Drug Spheroids and Uses Thereof for Eliminating or Reducing Conditions Such as Emesis and Diarrhea Wyeth LLC In force Ends no later than Nov 5, 2030 · Low confidence	Wyeth LLC	In force	Ends no later than Nov 5, 2030	Ends no later than Nov 5, 2030	Low confidence
US 8,518,446	Coated Tablet Formulations and Uses Thereof Wyeth LLC In force Term ends Nov 20, 2030 · High confidence	Wyeth LLC	In force	Term ends Nov 20, 2030	Term ends Nov 20, 2030	High confidence
19 more patents in this group · Pro

10 of 29 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 29, including 2 expired and 1 expiring within the 18 months from Nov 15, 2026.

Upgrade to Pro

11 of these are in force and held by Wyeth, LLC.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.